At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Pre-Market Trading 07-03 05:57:57 EDT
1.09
+0.00
-0.46%
High1.09
Low1.05
Vol83.97K
Open1.09
D1 Closing1.10
Amplitude3.65%
Mkt Cap18.04M
Tradable Cap17.70M
Total Shares16.55M
T/O90.36K
T/O Rate0.52%
Tradable Shares16.23M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Sector Update: Health Care Stocks Gain in Late Afternoon
BRIEF-Iterum Therapeutics Announces FDA Advisory Committee Meeting To Discuss NDA For Oral Sulopenem For Treating Uncomplicated Urinary Tract Infections
Iterum Therapeutics' Cash, Cash Equivalents And Short-term Investments Were $18.2 Million At March 31, 2024 Will Be Sufficient To Fund Its Operations Into 2025
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.